Clinical Trial Update: A Study to Evaluate ALN-2232 in Participants With Obesity [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update indicating that ALN-2232 for obesity is in a Phase 1/2 study and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• ALN-2232 (ALN-2232)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Obesity | Phase 1, Phase 2 | Status: RECRUITING